Health
Eli Lilly’s Stock Has Swung on Alzheimer’s Drug Developments. What Investors Need to Know. – Barron’s
Eli Lilly may have recently disappointed investors with a study’s data, but the approach being taken by it and other drugmakers to treat the disease seems to be…
When
Eli Lilly
presented the results of a small study of its Alzheimers disease therapy donanemab last weekend, investors were hoping for a miracle. It didnt materialize, and Lilly (ticker: LLY) shares, which had run up 11.7% when the company previewed the study back in January, slid 11.6% by the end of trading on Thursday.Those swings in the stock dont tell the real story of donanemab. The data that Lilly presented last Saturday were positive for Alzheimers drug development in general, and for…
-
General14 hours agoCoroner to examine treatment of woman who died three days after surgery performed by former Queensland premier’s partner
-
Noosa News16 hours agoSurgeon partner of former premier to testify over his patient’s death
-
Business14 hours agoWhy Antipa, Cettire, Magnetic Resources, and Steadfast shares are pushing higher
-
General15 hours agoToo skewed, too gentlemanly | The Spectator Australia